Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 4 de 4
Add filters

Main subject
Document Type
Year range
Lung India ; 39(SUPPL 1):S138, 2022.
Article in English | EMBASE | ID: covidwho-1857681


Background: Post COVID -19 infection has wide range of presentation, cavitation and fungal infections were very common in these patients especially when they are immune compromised. This is a case study of a post covid patient with cavitary consolidation and Rasmussen's aneurysm secondary to invasive aspergillus infection. Case Study: A 62 year old gentleman, hypertensive, diabetic and survivor of severe COVID-19 infection presented with low grade fever, breathlessness and cough with expectoration. The CT scan showed bilateral cavitary consolidation . Sputum examination showed aspergillus growth and MTB negative. Serum galactomannan was positive. While getting treated with antifungal therapy for invasive aspergillus infection, he had one episode of massive haemoptysis. CT angiography showed Rasmussen aneurysm and planned for bronchial artery embolization. But the patient was not willing for any urgent intervention and got discharged on request after stabilisation, warning signs were explained. After 5 days patient had massive haemoptysis followed by circulatory collapse. Patient could not be saved even after resuscitation measures and emergency intubation. Discussion: Rasmussen's aneurysm is a pseudo-aneurysmal dilatation of a branch of pulmonary artery secondary to chronic inflammation in a contiguous cavity. The reported incidence of such pathology is around 5% in cavitary lesions. It may ruptures into the cavity, producing massive haemoptysis. Conclusion: Rasmussen aneurysm itself is a very dangerous entity irrespective of its etiology. Early interventions to prevent the fatal haemoptysis is the management strategy as conservative treatment may not give us enough time to act at the time of emergency.

Lung India ; 39(SUPPL 1):S139, 2022.
Article in English | EMBASE | ID: covidwho-1856957


Background: Coronavirus disease 2019 (COVID-19) is a novel infectious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that emerged in Wuhan and has quickly spread worldwide. The mortality rate in critically ill patients with COVID-19 is high. This study analyzed clinical comorbidities in different groups to early identify harsh or critical patients. Objective: To identify different clinical symptoms and comorbidities in CIVID 19 patients. Methods: In this single-center, cross-sectional study, 142 COVID-19 patients were enrolled. Clinical characteristics and comorbidities were assessed. Results: Of the 142 patients, 92(64.8%) were male, with a mean age of (56.00±14.81)years. The patients were elderly above 60(n = 62,43.7%) and adults (n = 80). Of these, 92 (64.7%) had comorbidities. Patients with severe COVID pneumonia 102(71.8%)were admitted to the intensive care unit (ICU), and 12(8.5%) patients have died. On admission, the main clinical manifestations were Fever (90.1%), dyspnea (83.8%), cough (78.2%), Anosmia (19%),alteration of taste (13.4%), haemoptysis (10.6%),headache (5.6%) and conjunctivitis (3.5%). Common comorbidities were diabetes mellitus(42.3%),hypertension (27.5%),Obesity (10.6%),heart failure (6.3%),COPD (3.5%),Asthma (2.5%),coronary artery disease (2.1%), ILD (2.1%),Post tubercular (1.4%),and CKD,CLD less than one perent.19% patients had history of contact COVID 19 cases. Smoking was present in 8.5% of cases. One comorbidity has been seen in 46, two in 28, and more than two in 5 patients. Patients were divided into four groups: no comorbidities, one comorbidity, two comorbidities, and more than two comorbidities. ANOVA test was used and showed that the value of serum creatinine (p=.017), serum bilirubin (p=.006), and serum SGOT (P=.009) were significantly associated. Conclusion: Severe COVID 19 disease had the worst outcome. In addition, serum creatinine and serum bilirubin values differed significantly in different comorbidities groups.

Journal of Clinical and Diagnostic Research ; 15(11):OI1-OI3, 2021.
Article in English | Web of Science | ID: covidwho-1538818


Coronavirus Disease 2019 (COVID-19) is a respiratory and systemic illness that may progress to severe Acute Respiratory Distress Syndrome (ARDS). There is a pressing need to identify clinical predictors of severe COVID-19 which can help in risk stratification and prognostication. The COVID-19 pandemic tends to have more severe clinical presentation in older age group and in chronic diseases;Chronic Obstructive Pulmonary Disease (COPD) is one of them. COPD is the common cause of high mortality and morbidity worldwide. It is obvious to fear for patients with underlying COPD. Acute episode of exacerbation and COVID-19 pneumonia are the two pivotal differential diagnoses in contemporary era, in patients of COPD presenting with worsening dyspnoea. Mortality rate have been higher among COPD group of patients with the development of hypoxemia. Literature shows that pre-existing COPD worsens the risk of COVID-19 progression and leads to poorer prognosis. Even after recovery from the acute event, proper adherence to maintenance therapy for COPD (inhalational agents) continues to be of paramount importance and remains the standard of care. Because COPD remains a subset that is highly vulnerable for adverse outcomes with COVID-19 infection, preventive therapy should be directed towards-attenuation of contact with droplets, proper hand hygiene and maintenance of adequate nutritional status. The aim of this brief review is to know the burden and impact of COPD on COVID-19 pandemic and challenges in diagnosis and management of COPD patients.

ESMO Open ; 6(3): 100131, 2021 06.
Article in English | MEDLINE | ID: covidwho-1242977


BACKGROUND: European Society for Medical Oncology Women for Oncology (ESMO W4O) research has previously shown under-representation of female oncologists in leadership roles. As early reports suggested disproportionate effects of the COVID-19 pandemic on women, the ESMO W4O Committee initiated a study on the impact of the pandemic on the lives of female and male oncologists. METHODS: A questionnaire was sent to ESMO members and put on the ESMO website between 8 June 2020 and 2 July 2020. Questions focused on the working (hospital tasks, laboratory tasks, science) and home (household management, childcare, parent care, personal care) lives of oncologists during and after COVID-19-related lockdowns. RESULTS: Of 649 respondents, 541 completed the questionnaire. Of these, 58% reported that COVID-19 had affected their professional career, 83% of whom said this was in a negative way (85% of women versus 76% of men). Approximately 86% reported that COVID-19 had changed their personal life and 82% their family life. Women were again significantly more affected than men: personal life (89% versus 78%; P = 0.001); family life (84% versus 77%; P = 0.037). During lockdowns, women reported increased time spent on hospital and laboratory tasks compared with men (53% versus 46% and 33% versus 26%, respectively) and a significantly higher proportion of women than men spent less time on science (39% versus 25%) and personal care (58% versus 39%). After confinement, this trend remained for science (42% versus 23%) and personal care (55% versus 36%). CONCLUSIONS: The COVID-19 pandemic has adversely affected the professional and home lives of oncologists, especially women. Reduced research time for female oncologists may have long-lasting career consequences, especially for those at key stages in their career. The gender gap for promotion to leadership positions may widen further as a result of the pandemic.

COVID-19 , Adult , Communicable Disease Control , Female , Humans , Male , Medical Oncology , Middle Aged , Oncologists , Pandemics , SARS-CoV-2 , Surveys and Questionnaires , Young Adult